Breaking News

You are here » Indian-Commodity  :  Corporate  :  Repco Home Finance plans to raise Rs 100 crore through NCDs

01-Oct2016

Repco Home Finance plans to raise Rs 100 crore through NCDs

Repco Home Finance (RHF) is planning to raise Rs 100 crore through secured redeemable non-convertible debentures on Private Placement basis. The NCDs will mature on October 4, 2019. The Coupon rate on the bonds is at 8.5 per cent per annum. The Securities Allotment Committee of the Board of Directors will consider the same at a meeting on October 5, 2016.

Repco Home Finance is a professionally managed housing finance company headquartered in Chennai, Tamil Nadu. The company is operating through 80 branches and 13 satellite centres in Tamil Nadu, Andhra Pradesh, Kerala, Karnataka, Maharashtra, Gujarat, Odisha, West Bengal and Puducherry.


Related News

View all news

Bhansali Engineering Polymers reports 33% fall in Q2 net profit

Bhansali Engineering Polymers has reported results for second quarter ended September 30, 2018.The company has reported 32.71% fall in its net profit at Rs 16.89 crore for the quarter under review as compared......

Biocon, Mylan N.V. receive positive CHMP opinion for Ogivri

Biocon and Mylan N.V. have announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Ogivri, a biosimilar......

Lupin Neurosciences receives positive CHMP opinion for NaMuscla

Lupin Neurosciences, a specialty pharma division of Lupin has announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA),......

Top News

View all news

Bhansali Engineering Polymers reports 33% fall in Q2 net profit

Bhansali Engineering Polymers has reported results for second quarter ended September 30, 2018.The company has reported 32.71% fall in its net profit at Rs 16.89 crore for the quarter under review as compared......

Biocon, Mylan N.V. receive positive CHMP opinion for Ogivri

Biocon and Mylan N.V. have announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Ogivri, a biosimilar......

Lupin Neurosciences receives positive CHMP opinion for NaMuscla

Lupin Neurosciences, a specialty pharma division of Lupin has announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA),......